[New indication for selective COX-2 inhibitors. Now also approve for acute pain].
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004412:Dysmenorrhea / Q000188:drug therapy; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010146:Pain / Q000188:drug therapy*; D013450:Sulfones; D014098:Toothache / Q000188:drug therapy; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib
Neue Indikation für selektiven Cox-2-Hemmer. Jetzt auch bei akutem Schmerz zugelassen.